Pfizer Continues Positive Data Readouts For JAK Inhibitor Abrocitinib In Eczema

 
• By Joseph Haas
  
woman in a laboratory microscope with microscope slide in hand.toned image.
Pfizer continues to build a case for its JAK1 inhibitor in atopic dermatitis
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D